Document is current
Any future updates will be listed below
-
Authors
Herrera, Victoria L. M. https://orcid.org/0000-0001-8991-2134
Bosch, Nicholas A.
Lok, Judith J.
Nguyen, Mai Q.
Lenae, Kaitriona A.
deKay, Joanne T.
Ryzhov, Sergey V.
Seder, David B.
Ruiz-Opazo, Nelson
Walkey, Allan J.
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (5U54HL 119145-07, 1KL2TR001411, 5U54GM11516-03, 1UL1TR001430)
- License Information
-
More Information
Article History
Received: 15 January 2023
Accepted: 24 March 2023
First Online: 18 April 2023
Declarations
:
: Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as most recently amended ().At Boston Medical Center (BMC), the protocol study number is H-36744, study title: Humanized anti-DEspR antibody therapy for Acute Lung Injury (ALI/Acute Respiratory Distress Syndrome), and approval by Boston University’s Institutional Review Board on 12–01-2019. At Maine Medical Center (MMC), the protocol study number is 1598969–16, with study title “IT-19 Identification of molecular treatment targets for COVID-19”, and approval by Maine Medical Center’s Institutional Review Board on 5/8/2020. Clinical data and blood sample collections followed IRB approved protocols.
: Not applicable.
: Boston University holds awarded patents on DEspR as novel therapeutic approach for cancer, stroke, COVID-19, NETosis and activated neutrophils. VLMH and NRO are co-inventors in patents filed by Boston University.
